Seminars in Oncology
Volume 33, Supplement 6 , Pages 3-11, April 2006

Systemic Therapy for Ovarian Cancer: Current Status and New Treatments

  • Robert F. Ozols

      Affiliations

    • Dr Ozols has served as a consultant to Bristol-Myers Squibb, Eli Lilly and Company, Genentech, and Unither Pharmaceuticals.
    • Corresponding Author InformationAddress reprint requests to Robert F. Ozols, MD, PhD, Fox Chase Cancer Center, 333 Cottman Ave, Philadelphia, PA 19111, USA

Fox Chase Cancer Center, Philadelphia, PA.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

PII: S0093-7754(06)00118-7

doi:10.1053/j.seminoncol.2006.03.011

Seminars in Oncology
Volume 33, Supplement 6 , Pages 3-11, April 2006

Article Tools

* Image Usage & Resolution